The stock last traded at $1.90 which is marginally under the 50 day moving average of $2.05 and quite a bit higher than the 200 day moving average of $1.68. The 50 day moving average went down $-0.15 or -7.48% and the 200 day average went up by +12.80%. (NASDAQ:AEZS) shares saw light trading volume with 89K shares changing hands on Tuesday. Shares saw a steep decrease in trading volume of 82.60% under the normal average daily volume.
Traders are more bullish on Aeterna Zentaris Inc. considering the decrease in short interest. The company experienced a fall in short interest between September 29, 2017 and October 13, 2017 of -0.90%. Short shares fell from 1,028,568 to 1,019,295 over that period. The short-interest ratio decreased to 1.0 and the short interest percentage is 0.06% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (AEZS). As of the end of the quarter Morgan Stanley had sold 100 shares trimming its holdings by 10.0%. The value of the investment in Aeterna Zentaris Inc. went from $3,000 to $1,000 a change of $2,000 quarter to quarter. Renaissance Technologies LLC cut its investment by shedding 82,000 shares a decrease of 38.4%. Renaissance Technologies LLC owns 131,433 shares worth $131,000. The total value of its holdings decreased 79.5%.
Kcg Holdings, Inc. added to its stake by buying 450 shares an increase of 2.5% from 03/31/2017 to 06/30/2017. Kcg Holdings, Inc. controls 18,577 shares valued at $19,000. The value of the position overall is down by 64.8%. As of quarter end Cutler Group LP had acquired a total of 900 shares growing its stake by 180.0%. The value of the total investment in Aeterna Zentaris Inc. decreased from $2,000 to $2,000 decreasing 0.0% for the reporting period.
In the last earnings report the EPS was $-1.71 and is projected to be $-1.02 for the current year with 16,110,000 shares currently outstanding. Next quarter’s EPS is estimated at $-0.26 and the next full year EPS is anticipated to be $-0.29.
Aeterna Zentaris Inc., launched on October 12, 1990, is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is involved in drug development activities and in the promotion of products for others. The Business’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Business’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc..